List of Excipients in Branded Drug ULTRATAG

« Back to Dashboard

ULTRATAG Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

ULTRATAG RBC is a technetium Tc 99m-labeled red blood cell diagnostic kit, not a conventional therapeutic drug. Its commercial value depends on reliable in vitro red-cell labeling, short preparation time, radiopharmaceutical workflow integration, and consistent performance in cardiac blood-pool imaging and gastrointestinal bleeding localization. The excipient estate is likely weaker than the process, packaging, quality-control, and automation opportunities surrounding the kit.

What is ULTRATAG and how does its formulation work?

ULTRATAG RBC is used to prepare autologous red blood cells labeled with technetium Tc 99m. The labeled cells are administered intravenously for blood-pool imaging, including cardiac first-pass and gated imaging, and for detecting sites of gastrointestinal bleeding.[1]

The kit does not contain the final radioactive product at manufacture. The nuclear pharmacy or imaging facility adds sodium pertechnetate Tc 99m and combines the preparation with the patient's red blood cells. The formulation therefore has two functional stages:

1. Intracellular reduction and trapping of technetium within red blood cells.
2. Maintenance of red-cell integrity and acceptable labeling efficiency during preparation and administration.

The labeled red cells provide a circulating intravascular imaging signal. The excipients support the labeling chemistry, pH, osmotic environment, and cell compatibility.

What excipients are used in ULTRATAG?

Public product information identifies excipient classes including stannous chloride dihydrate, sodium citrate, and dextrose. Hydrochloric acid and sodium hydroxide may be used for pH adjustment.[1,2]

Formulation component	Primary technical role	Commercial relevance
Stannous chloride dihydrate	Reduces pertechnetate technetium to a form that binds to red cells	Core labeling chemistry; potential process and stability claim area
Sodium citrate	Chelating and buffering support; helps control metal-ion chemistry	May affect labeling efficiency and cell compatibility
Dextrose	Tonicity and cell-environment support	Useful for stability and hemolysis control
Hydrochloric acid or sodium hydroxide	pH adjustment	More likely a manufacturing and specification element than a standalone patent asset
Sodium pertechnetate Tc 99m	Radioactive technetium source added at use	Supplied through the radiopharmaceutical chain rather than as a conventional kit excipient

The commercial objective is not to increase systemic exposure. It is to improve labeling yield, reduce preparation failures, preserve erythrocyte morphology, and make the kit easier to use in high-throughput nuclear medicine departments.

What formulation attributes create commercial value for ULTRATAG?

The highest-value attributes are operational rather than pharmacokinetic.

Labeling efficiency

A stronger product can produce a high percentage of technetium-associated radioactivity in the red-cell fraction while limiting free pertechnetate and plasma-bound activity. Better labeling can improve image quality and reduce repeat imaging.

Potential development targets include:

• Higher and more reproducible labeling efficiency.
• Lower residual free technetium.
• Less sensitivity to pertechnetate activity or volume.
• Wider acceptable operating time after reconstitution.
• Greater robustness across patient hematocrit levels.
• Reduced variation between technologists and nuclear pharmacies.

Red-cell integrity

The formulation must avoid clinically meaningful hemolysis, aggregation, altered cell deformability, or premature clearance. A commercial successor could target:

• Lower hemolysis during labeling.
• Better preservation of cell morphology.
• Reduced aggregation during preparation and injection.
• More consistent recovery of labeled cells in circulation.
• Compatibility with pediatric and geriatric blood volumes.

Workflow simplicity

Nuclear medicine departments value a preparation that minimizes hands-on steps and radioactive handling. Commercial opportunities include:

• Fewer transfers between vials and syringes.
• A closed or semi-closed transfer system.
• Barcode-based dose and patient identification.
• Ready-to-use or simplified reconstitution formats.
• Integration with automated dose dispensers.
• Clearer separation of patient-specific materials from stock kit components.

The excipient composition can support these improvements, but the strongest protection may arise from the combination of formulation, container closure, preparation sequence, and quality-control method.

What formulations could be protected around ULTRATAG?

A new entrant is unlikely to obtain broad protection over the basic concept of stannous-mediated technetium labeling of erythrocytes. The core chemistry is old, and the product's public labeling has been available for decades. More defensible claims would focus on specific combinations and measurable performance outcomes.

Formulation patent opportunities

Potential claim categories include:

Claim area	Example commercial concept	Relative patent strength
Excipient ratio	Defined stannous, citrate, and carbohydrate ranges that improve labeling consistency	Moderate if linked to unexpected performance
Oxygen control	Formulation or vial headspace that limits oxidation of stannous ion	Moderate
Stability	Lyophilized or otherwise stabilized kit with improved shelf life	Moderate to strong if supported by comparative data
Cell compatibility	Composition that reduces hemolysis or aggregation	Moderate
Reconstitution window	Kit that maintains performance across a wider time and activity range	Moderate
Container system	Low-adsorption vial, transfer device, or dual-chamber package	Moderate
Automation	Kit designed for closed-system or robotic preparation	Stronger when combined with apparatus and method claims
Quality control	Rapid assay for free pertechnetate or labeling yield	Potentially strong as a process or diagnostic QC claim

A patent strategy based only on substituting one buffer or sugar for another would face obviousness and enablement challenges. The better approach is to link excipient selection to a documented technical result, such as lower free technetium, reduced hemolysis, or improved performance after an extended preparation interval.

Could a liquid or ready-to-use version compete with ULTRATAG?

A liquid formulation could reduce preparation steps, but radioactivity logistics complicate the proposition. Tc 99m has a physical half-life of approximately six hours, so a centralized ready-to-use product must account for decay, shipping time, dose calibration, and delivery schedules.[3]

A nonradioactive, ready-to-label liquid kit could be commercially attractive if it maintains stannous activity and cell compatibility during refrigerated storage. The main development risks would be oxidation, microbial control, container interaction, and stability after opening.

A dual-chamber package could separate the reducing formulation from a stabilizing or buffering component until use. This could create stronger product differentiation than a simple excipient substitution.

What is the FDA regulatory status of ULTRATAG?

ULTRATAG RBC is an FDA-approved diagnostic radiopharmaceutical kit regulated through the drug approval pathway. It is used with sodium pertechnetate Tc 99m to prepare labeled autologous red blood cells.[1]

Regulatory issue	ULTRATAG assessment
Product type	Diagnostic radiopharmaceutical kit
Active imaging species	Technetium Tc 99m-labeled autologous red blood cells
Final radioactive product	Prepared at or near the imaging facility
FDA pathway	Approved drug product pathway
Primary clinical uses	Blood-pool imaging and gastrointestinal bleeding localization
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Generic pathway	Potentially complex because the product is a kit combined with patient-specific cells and radionuclide
Main regulatory burden for a successor	Chemistry, manufacturing, controls; labeling performance; cell compatibility; radiopharmaceutical handling; clinical or bridging data as required

A competing product could pursue an NDA, a 505(b)(2) application, or another FDA pathway depending on the extent of formulation, process, labeling, and clinical differences. A simple change to inactive ingredients would not automatically guarantee an abbreviated approval route because the product's performance depends on preparation conditions and patient-derived cells.

What is the Orange Book and patent status of ULTRATAG?

The commercially relevant patent question is whether any unexpired, FDA-listed patents block an equivalent kit. No broadly recognized active Orange Book patent estate is associated with the basic ULTRATAG RBC labeling concept in the public product materials reviewed for this analysis.[1,4]

The practical exclusivity profile is therefore driven by regulatory approval, manufacturing know-how, supply reliability, customer familiarity, and institutional protocols rather than by a strong composition-of-matter patent.

Exclusivity category	Assessment
Composition-of-matter exclusivity	Expired or unavailable for the underlying labeling chemistry
New chemical entity exclusivity	Not applicable
Biologic exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Orange Book patent blocking risk	No major active listing identified
Formulation patent risk	Depends on later-filed, product-specific claims
Method-of-use patent risk	Likely limited for established imaging indications
Regulatory dependence	High because a competing kit must demonstrate reliable preparation and patient safety

Are Paragraph IV challenges relevant?

Paragraph IV litigation is primarily relevant when a generic applicant seeks approval while challenging an unexpired Orange Book-listed patent. It is not the central competitive pathway for ULTRATAG if no blocking listed patent remains.

A competitor may instead face:

• FDA questions over pharmaceutical equivalence.
• Requirements to demonstrate comparable labeling performance.
• Clinical and analytical bridging requirements.
• Manufacturing inspection issues.
• Radiopharmaceutical distribution and decay-management problems.
• Facility-specific validation requirements.

The absence of a major listed patent does not eliminate market-entry barriers. It shifts the dispute from patent validity toward regulatory equivalence and operational execution.

When does ULTRATAG lose exclusivity?

ULTRATAG's core exclusivity has already eroded from a small-molecule patent perspective. The product's commercial protection now resembles mature diagnostic radiopharmaceutical protection:

• Brand recognition among nuclear medicine departments.
• Established preparation procedures.
• Existing hospital formularies and protocols.
• Supplier qualification and quality history.
• Distribution relationships.
• Familiarity with the kit's labeling behavior.

The key timing issue is not a single patent expiration date. It is the time required for a competing manufacturer to develop, validate, file, manufacture, and distribute a reliable alternative.

What commercial opportunities exist for ULTRATAG competitors?

Lower-cost generic or branded-generic kit

A competitor could target hospitals and independent imaging centers with a lower acquisition price. The strongest product would preserve labeling reliability while reducing preparation complexity and waste.

Extended-stability formulation

A formulation with longer post-reconstitution stability could reduce discarded doses and improve scheduling flexibility. This opportunity is commercially relevant because Tc 99m supply and imaging appointments are time-sensitive.

Closed-system preparation

A closed transfer device could reduce radiation exposure, contamination risk, and operator variability. The product could be sold as a kit-plus-device platform and protected through apparatus, method, and packaging claims.

Automated nuclear pharmacy integration

Automation is a significant opportunity for centralized radiopharmacies. A kit designed for robotic reconstitution, dose withdrawal, and documentation could support premium pricing and institutional contracts.

Pediatric and low-blood-volume applications

A lower-volume kit or flexible dosing format could address pediatric imaging centers. The product would need tight control of residual volume, dose accuracy, and red-cell handling.

Gastrointestinal bleeding workflow

The product could be paired with software or protocol support for serial imaging and rapid localization. The commercial offering could include training, standardized preparation, and integration with SPECT/CT workflows.

International expansion

Geographic opportunities are strongest in markets with established Tc 99m generator access and nuclear medicine infrastructure. Regulatory filings must address local radiopharmaceutical rules, import controls, cold-chain requirements, and generator supply. The product's short-lived radionuclide component makes local manufacturing or regional radiopharmacy partnerships more important than conventional global tablet distribution.

Which companies and products compete with ULTRATAG?

Competition comes from several categories rather than one direct generic substitute.

Competitor category	Examples of alternatives	Competitive effect
Other Tc 99m red-cell labeling kits	In vitro or modified labeling systems	Direct product competition
In vivo red-cell labeling	Tc 99m pyrophosphate or related protocols	Lower preparation burden but different performance profile
Nuclear imaging alternatives	Tc 99m agents used for related studies	Indication-specific substitution
Cardiac imaging	Echocardiography, cardiac MRI, CT, PET	Reduces demand for selected blood-pool studies
GI bleeding diagnosis	CT angiography, catheter angiography, endoscopy	Competes on speed, localization, and intervention
Hospital-compounded workflows	Local radiopharmacy preparation	Price and supply substitute

ULTRATAG's strongest defense is workflow reliability in applications where serial blood-pool imaging or prolonged observation is clinically useful. Its weaker areas are settings where CT angiography or endoscopy can provide faster anatomic localization.

How strong is the ULTRATAG patent estate?

The patent estate is likely weak for broad chemistry claims and stronger for any later-developed improvements that combine:

• A defined excipient system.
• A specified preparation sequence.
• A validated labeling-efficiency threshold.
• Reduced hemolysis or aggregation.
• A closed transfer device.
• A robotic preparation method.
• A specialized container or dual-chamber presentation.

The best investment thesis is therefore not acquisition of legacy excipient patents alone. It is development of a differentiated preparation platform with measurable operational advantages and patent protection across formulation, device, manufacturing, and use.

What revenue exposure and licensing opportunities exist?

Public sources do not provide a reliable product-level revenue figure for ULTRATAG. Revenue exposure should be modeled through procedure volume, kit utilization, hospital purchasing share, and the availability of Tc 99m supply rather than through conventional prescription volume.

Potential licensing targets include:

• Excipient stabilization technology for stannous formulations.
• Low-oxygen vial and stopper systems.
• Automated radiopharmaceutical compounding equipment.
• Rapid free-pertechnetate testing.
• Barcode and dose-tracking software.
• Regional radiopharmacy distribution.
• Formulation technology that extends usable preparation time.

A licensing deal would have the strongest commercial logic if it combines a formulation asset with a device or workflow asset. A standalone buffer or tonicity patent would provide limited negotiating leverage unless it produces clear performance gains.

What patent litigation and settlement risks affect ULTRATAG?

No major public patent-litigation or Paragraph IV settlement framework is central to the established ULTRATAG market based on the cited FDA and product sources. Future disputes would more likely concern:

• Infringement of a new formulation patent.
• Device claims covering closed-system preparation.
• Trade secrets involving kit manufacture or stannous stability.
• Regulatory exclusivity for a differentiated indication.
• Contractual supply and distribution rights.

Manufacturing know-how may be more valuable than legacy composition claims. A competitor that reproduces the excipient list but fails to control oxygen exposure, moisture, vial closure, or stannous oxidation may not reproduce the product's clinical performance.

Key Takeaways

• ULTRATAG RBC is a Tc 99m red-blood-cell labeling kit, not a conventional systemic drug.
• Its core excipients support reduction chemistry, buffering, tonicity, and erythrocyte compatibility.
• Broad excipient patent protection is likely limited because the underlying chemistry is mature.
• Stronger opportunities exist in stability, closed-system preparation, automation, quality control, and reduced hemolysis.
• Biosimilar risk is not relevant; generic entry would involve a complex radiopharmaceutical-kit assessment.
• No major active Orange Book patent barrier was identified for the basic product concept in the cited sources.
• Commercial differentiation should focus on workflow reliability, waste reduction, preparation time, and supply continuity.
• The most attractive licensing strategy combines formulation technology with a device, automation system, or radiopharmacy platform.

FAQs

Does ULTRATAG contain technetium Tc 99m when it is sold?

No. ULTRATAG is supplied as a nonradioactive kit. Sodium pertechnetate Tc 99m is added during preparation, together with the patient's red blood cells.[1]

Can ULTRATAG be replaced by a conventional generic injection?

Not directly. The product is a kit used to prepare patient-specific labeled red blood cells. A competing product must reproduce the preparation chemistry and demonstrate acceptable labeling, cell compatibility, sterility, and performance.

Are ULTRATAG excipients pharmacologically active?

They are not intended to provide therapeutic activity. Stannous chloride has a critical chemical function because it reduces technetium for red-cell labeling. Citrate and dextrose support the formulation environment.

What is the most valuable improvement for a next-generation ULTRATAG competitor?

A closed, low-variability preparation system that extends usable preparation time and reduces free technetium, hemolysis, operator handling, and radioactive waste would offer the clearest commercial differentiation.

Can a ULTRATAG competitor obtain method-of-use patents?

Potentially, but broad claims covering established cardiac blood-pool imaging or gastrointestinal bleeding localization would face prior-art challenges. Narrower claims tied to a specific preparation protocol, imaging workflow, patient subgroup, or quality-control threshold would be more defensible.

References

1. U.S. Food and Drug Administration. (n.d.). ULTRATAG RBC kit for the preparation of technetium Tc 99m-labeled red blood cells: Prescribing information.
2. DailyMed. (n.d.). ULTRATAG RBC: Technetium Tc 99m-labeled red blood cells kit. National Library of Medicine.
3. U.S. Nuclear Regulatory Commission. (n.d.). Technetium-99m radiopharmaceutical information and physical half-life data.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.